Q.01

What does good manufacturing practice mean in Australia?

In Australia, good manufacturing practice (GMP) for human therapeutic goods is a legal requirement, not just guidance. The Therapeutic Goods Act 1989 lets the Minister set "manufacturing principles", which may include codes of GMP. The current instrument makes the PIC/S Guide to GMP (PE 009-17) binding for medicines, active pharmaceutical ingredients (APIs) and sunscreens. A separate Australian Code of GMP applies to blood, blood components, haematopoietic progenitor cells and certain biologicals.

What the Act says (Part 3-3, compilation 89, effective 5 September 2025)

  • Section 36: the Minister "may" set written principles for manufacturing therapeutic goods for use in humans [1]. They can cover:

    • standards for premises and equipment
    • quality assurance and quality control
    • staff qualifications and experience
    • manufacturing practices
    • other matters affecting quality, safety and efficacy

    They "may include codes of good manufacturing practice", and they are legislative instruments.

  • Licence needed: carrying out a step in manufacturing human-use goods at premises in Australia without a licence covering that step at those premises is an offence. The exceptions are exempt goods and exempt persons. Penalties go up to 5 years' imprisonment or 4,000 penalty units where harm results or is likely, and there is also a strict-liability offence of 100 penalty units [2]. Exemptions are set in the regulations [3].

  • Grant of licence (s 38): the Secretary must grant a licence unless satisfied of one of the refusal grounds [4]. These include:

    • the applicant "will be unable to comply with the manufacturing principles"
    • a site is not satisfactory
    • a fit-and-proper ground (for example, convictions within the previous 10 years)
  • Conditions every licence carries (s 40(4)), unless the licence says otherwise [5]:

    • the goods must meet any applicable standard
    • the holder must observe the manufacturing principles
    • the holder must report information suggesting harm, reduced efficacy or unacceptable quality, safety or efficacy
    • authorised persons must be allowed to enter and inspect sites, take samples, question staff and see documents

The current instrument: Therapeutic Goods (Manufacturing Principles) Determination 2020, Compilation No. 4, 1 September 2025 (Federal Register of Legislation)

  • Medicines, APIs and sunscreens:
    • Manufacturing "must comply with applicable procedures and requirements" in the PIC/S Guide to GMP (PE 009-17, 25 August 2023). Annex 4 (veterinary non-immunologicals), Annex 5 (veterinary immunologicals) and Annex 14 (products from human blood or plasma) are left out.
    • Where the Guide says "should", Australian manufacturers must follow it. The only exception is where the manufacturer satisfies a TGA officer that skipping the step, or using an alternative, does not increase the risk of harm or of failing a standard or a registration or listing condition, and does not depart from record-keeping requirements.
    • Annex provisions marked as voluntary are not included.
    • This also covers biologicals that contain live animal cells, tissues or organs.
  • Timing of the PE 009-17 change:
    • It applies to manufacturing from 1 September 2025.
    • For sterile medicines and sterile APIs, Annex 1 clauses 2.1, 2.3, 7.14 and 9.31 apply only from 1 March 2026. That date has now passed, so they are in force.
    • Before this, PE009-16 applied, from 3 June 2024 (TGA search listing).
  • Blood, blood components, haematopoietic progenitor cells, and biologicals without live animal cells, tissues or organs:
    • These follow the Australian Code of GMP for human blood and blood components, human tissues and human cellular therapy products (Version 1.0, April 2013), with the same "should means must" rule.
    • A licence application for blood, blood components or haematopoietic progenitor cells must include a technical master file, and manufacturing must be consistent with it.
    • Processing plasma collected outside Australia requires a plasma master file accepted by the TGA.

Medical devices are not covered by the manufacturing principles. Instead, s 41DA lets the regulations set "conformity assessment procedures" for manufacturers, which can include quality management systems, certification, inspections and record keeping [6]. TGA guidance sets out the procedures:

  • Full Quality Assurance requires a full ISO 13485 system, audited by a conformity assessment body.
  • Production Quality Assurance requires ISO 13485 excluding design and development (clause 7.3).
  • In-house IVD laboratories use ISO 15189.

[7]

Veterinary products are outside the TGA scheme: s 36 covers goods "for use in humans", and the PIC/S veterinary annexes are excluded. The APVMA publishes its own Australian Code of GMP for Veterinary Chemical Products. A draft revised code appeared in search results dated August 2026. The APVMA website did not respond, so I couldn't confirm the details of its regime.

Approach: I read the Therapeutic Goods Act 1989 and TGA medical device guidance in our datasets, plus the official Manufacturing Principles Determination on the Federal Register of Legislation. The TGA and APVMA websites did not respond, so I could not read TGA guidance on overseas GMP clearance or the APVMA's veterinary GMP pages.

Q.02

How do APVMA and TGA manufacturing requirements differ?

The two regimes are built the same way: you need a site licence for each manufacturing step, you must follow manufacturing principles, and both have statutory licence conditions and fit-and-proper tests. Where they differ is who sets the GMP standard and how much is written into the law itself. The TGA's standard is a ministerial instrument that adopts the PIC/S Guide (from the previous answer). For veterinary products, the APVMA sets its own manufacturing principles, and the Agvet Regulations require licensees to follow the APVMA's own Australian GMP Code. The Regulations also spell out record-keeping, audit and subcontracting rules directly. The APVMA scheme also covers fewer products: agricultural chemicals and many low-risk veterinary products need no manufacturing licence at all.

Side-by-side

PointTGA (Therapeutic Goods Act 1989, compilation 89, 5 Sep 2025)APVMA (Agvet Code compilation 34, 14 Oct 2024; Agvet Regulations compilation 49, 1 Oct 2025)
Who sets the principlesThe Minister "may" determine them for goods "for use in humans"; they may include GMP codes and are legislative instruments [1]The APVMA determines them under s 23 of the Agricultural and Veterinary Chemicals Act 1994 [8]. Licensees "must" manufacture in line with the manufacturing principles and the Australian GMP Code, meaning the APVMA's Australian Code of GMP for Veterinary Chemical Products (reg 61(3A); reg 3) [9][10]
GMP standard usedPIC/S Guide PE 009-17, adopted by the Manufacturing Principles Determination 2020 (Federal Register of Legislation)The APVMA's own code (see row above)
Products outside the licensing schemeExempt goods and exempt persons, set in the regulations [2]Part 8 does not apply to: listed and reserved chemical products; all agricultural chemical products; some ingredients; research and pilot-plant products; dilute non-sterile homeopathics; skin cleansers and shampoos; coat conditioners; hoof protectants; sheep branding substances; and listed stockfood additives (reg 59) [11]
How a licence is structuredCovers specified steps for specified goods at each site [4]Risk-based categories (definitions in reg 3) [10]:
• Cat 1: sterile or immunobiological products
• Cat 3: external ectoparasiticides
• Cat 4: premixes and stockfood supplements
• Cat 6: only certain steps (processing, packaging, labelling, storage, sterilising, testing, release)
• Cat 2: everything else
• Multi-category licences also exist
Penalty for manufacturing without a licenceUp to 5 years' imprisonment or 4,000 penalty units where harm results or is likely; 12 months or 1,000 units otherwise; 100 units strict liability [2]240 penalty units (strict liability), and it is also a civil penalty provision. Breaching a licence condition is 120 units (s 121) [12]. Infringement notice amounts depend on the licence category [13]
Grounds for refusing a licenceUnable to comply with the principles; unsatisfactory site; s 9K prohibitions; fit-and-proper tests looking back 10 years [4]Similar 10-year tests, plus failing to comply with a manufacturing principle in the previous 5 years (s 123(1)(f)) [14]. If directed, the applicant must undergo a pre-licence audit (reg 59E) [15]
Conditions every licence carries by lawMeet standards; observe the principles; report information on harm, efficacy or quality; allow entry, questioning, and access to documents and samples (s 40(4)) [5]Meet standards; allow inspectors in to use monitoring powers; comply with conditions set in the regulations (s 126(4)) [16]

Extra detail in the APVMA Regulations (reg 61)

These apply to every APVMA licence [9]:

  • Records: you must keep records of materials and suppliers, process controls, product tests, stability studies, and complaints or product failures.
  • Batches: each batch needs a batch number.
  • Retention: keep records and, where reasonable, batch samples on site for at least 12 months after expiry. If there is no expiry date, keep them for 6 years after manufacture was completed.
  • Nominated person: the person you nominate to control production or quality control must keep that control. If you replace them, you must tell the APVMA their name, qualifications and experience (reg 62) [17].
  • Subcontracting: allowed only to APVMA-licensed sites, or to overseas sites the APVMA has found meet a comparable standard (reg 61(7A)). A contractor doing packaging, labelling or testing must be supervised, and responsibilities must be recorded in writing.
  • GMP audits: these happen when the APVMA CEO directs. You must notify a critical non-conformance in writing within 3 working days and submit the signed audit report with a corrective action plan.

Other APVMA-specific points

  • Single-step exemption: someone who only packages, labels, analyses or tests is exempt if another person's licence permits it. Applying only a name, address or registration number label is also exempt (reg 59A) [18].
  • Overseas manufacturers: handled through a condition on the product's registration rather than a licence. If directed, the registrant must provide GMP evidence, such as audit reports, which the APVMA then assesses (reg 71B) [19].
  • Fees: $900 to apply. Annual fees are $7,500 (category 1 or multi-category), $5,000 (categories 2 to 4) and $1,800 (category 6), with a 50% reduction from the second year if the notional wholesale value is under $50,000 [20].

Medical devices have no equivalent on the APVMA side. Under the TGA they follow conformity assessment procedures (quality management systems, certification, monitoring) rather than manufacturing principles [6].

Approach: I compared Part 3-3 of the Therapeutic Goods Act with Part 8 of the Agvet Code and the Agvet Regulations. I did not read the text of the APVMA's Australian GMP Code or its s 23 manufacturing principles instrument, or the TGA's rules on overseas manufacturers and fees, so the table does not compare those.

Q.03

How can I check whether an Australian manufacturer is licensed?

Which register you check depends on what the manufacturer makes. For veterinary chemical products, I can search the APVMA's list of licensed manufacturers right here: the copy I searched holds 154 current licences. Each one gives the licence number, holder, site address, licence category and the manufacturing steps it covers. For human therapeutic goods, the TGA publishes its own list of licensed Australian manufacturers. That list is not in our datasets, and the TGA website timed out when I tried to open it.

Veterinary products (APVMA list) You can search by licence number, holder name, address, product category or manufacturing step. Two examples from the list:

  • Licence 1112, Vetlab Sterile Pty Ltd, North St Marys NSW. Category 1 (sterile products). Steps include formulation, aseptic filling, heat and filtration sterilisation, packaging, labelling, physical testing, storage and release for supply [21].
  • Licence 6199, Wesley Community Services Limited, Dundas NSW. Category 6 (all non-sterile and sterile dosage forms). It covers only secondary packaging, secondary labelling, physical testing and storage [22].

Finding the company's name is not enough. Check that its licence covers the right product category and the step it actually carries out, at that address. In the 6199 example above, the licence does not cover formulation or release for supply.

A missing name does not always mean the company is operating unlawfully:

  • Exempt products: Part 8 does not apply to agricultural chemical products, listed and reserved chemical products, and several low-risk veterinary products (reg 59) [11].
  • Single-step operators: a business that only packages, labels, analyses or tests is exempt if another person's licence permits that step (reg 59A) [18].
  • Overseas manufacturers: they hold no Australian licence. Their GMP evidence is dealt with through a condition on the product's registration (reg 71B) [19].

If you give me a company name or licence number, I can look it up now.

Human therapeutic goods (TGA)

Approach: I searched the APVMA licensed manufacturers list and the captured TGA news and medical device guidance. The TGA licensed manufacturer register is not in our datasets, and the TGA website did not respond, so the TGA links above are the official pages, not ones I could read.

Q.04